Citigroup Upgrades Arcturus Therapeutics to Buy, Raises Price Target to $20
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsUpgradesPrice Target
Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and raises the price target from $8 to $20.
Citigroup analyst Yigal Nochomovitz upgrades Arcturus Therapeutics (NASDAQ:ARCT) from Neutral to Buy and raises the price target from $8 to $20.